In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' New Kind of Pharma Deal

Executive Summary

Novartis' two-step, $39 billion agreement to take a majority share of eye-group Alcon represents a very new kind of pharma deal: with pharma re-defined to include consumer care and surgery; and, for the first few years at least, with the buyer remaining an arm's length investor.

You may also be interested in...



Alcon Shareholders Reject Novartis Offer As Inadequate

When Novartis announced on Jan. 4 its intention to not only exercise its option to purchase Nestle's remaining 52% stake in eye-care group Alcon, but also to buy out the remaining, minority-held 23%, CEO and Chairman Daniel Vasella claimed this second step would "create clarity for all stakeholders.

Alcon Shareholders Reject "Inadequate" Novartis Offer

When Novartis announced on Jan. 4 its intention to not only exercise its option to purchase Nestle's remaining 52 percent stake in eye-care group Alcon, but also to buy out the remaining, minority-held 23 percent, CEO and Chairman Daniel Vasella claimed this second step would "create clarity for all stakeholders

Alcon Shareholders Reject Novartis Offer As Inadequate

When Novartis announced on Jan. 4 its intention to not only exercise its option to purchase Nestle's remaining 52% stake in eye-care group Alcon, but also to buy out the remaining, minority-held 23%, CEO and Chairman Daniel Vasella claimed this second step would "create clarity for all stakeholders.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel